SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Health Catalyst, Inc. (HCAT) has a negative trailing P/E of -0.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -254.57%, forward earnings yield 10.04%. PEG 0.23 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.23); analyst target implies upside (+167.9%).
- Forward P/E 10.0 — analysts expect a return to profitability with estimated EPS of $0.11 for FY2026.
- PEG Ratio 0.23 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -254.57% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 10.04% as earnings recover.
- Analyst consensus target $3.00 (+167.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HCAT
Valuation Multiples
P/E (TTM)-0.4
Forward P/E10.0
PEG Ratio0.23
Forward PEG0.23
P/B Ratio0.28
P/S Ratio0.23
EV/EBITDA13.4
Per Share Data
EPS (TTM)$-2.51
Forward EPS (Est.)$0.11
Book Value / Share$3.46
Revenue / Share$4.38
FCF / Share$-0.07
Yields & Fair Value
Earnings Yield-254.57%
Forward Earnings Yield10.04%
Dividend Yield0.00%
SharesGrow IV$1.38 (+23.2%)
Analyst Target$3.00 (+167.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2017 |
-23.1 |
0.00 |
-4.19 |
14.88 |
- |
| 2018 |
-17.5 |
-0.55 |
-2.90 |
9.66 |
- |
| 2019 |
-10.8 |
-0.25 |
3.24 |
4.20 |
- |
| 2020 |
-15.0 |
1.60 |
6.23 |
9.11 |
- |
| 2021 |
-12.3 |
-1.12 |
3.60 |
7.78 |
- |
| 2022 |
-4.2 |
0.20 |
1.34 |
2.07 |
- |
| 2023 |
-4.4 |
0.24 |
1.42 |
1.77 |
- |
| 2024 |
-6.1 |
0.14 |
1.17 |
1.39 |
- |
| 2025 |
-0.9 |
-0.01 |
0.68 |
0.54 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-1.69 |
$73.08M |
$-47.04M |
-64.4% |
| 2018 |
$-2.23 |
$112.57M |
$-61.98M |
-55.1% |
| 2019 |
$-3.21 |
$154.94M |
$-60.1M |
-38.8% |
| 2020 |
$-2.91 |
$188.85M |
$-115.02M |
-60.9% |
| 2021 |
$-3.23 |
$241.93M |
$-153.21M |
-63.3% |
| 2022 |
$-2.54 |
$276.24M |
$-137.4M |
-49.7% |
| 2023 |
$-2.09 |
$295.94M |
$-118.15M |
-39.9% |
| 2024 |
$-1.15 |
$306.58M |
$-69.5M |
-22.7% |
| 2025 |
$-2.55 |
$311.14M |
$-177.97M |
-57.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.11 |
$0.10 – $0.12 |
$280.23M |
$273.67M – $286.95M |
5 |
| 2027 |
$0.14 |
$0.13 – $0.15 |
$279.81M |
$271.66M – $283.96M |
5 |
| 2028 |
$0.23 |
$0.22 – $0.24 |
$293.98M |
$281.83M – $304.43M |
1 |
